A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
← catalyst calendarNCT07062965 · readout in 337 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
202
Countries
Australia, Belgium, Brazil +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-05 | actual | When the study began enrolling |
| Primary completion | 2027-07-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: PF-07248144
- Drug: Fulvestrant
- Drug: Everolimus
- Drug: Exemestane
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured From the date of randomization until disease progression or death due to any cause (up to approximately 2 years)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed